JP2025508406A5 - - Google Patents

Info

Publication number
JP2025508406A5
JP2025508406A5 JP2024548386A JP2024548386A JP2025508406A5 JP 2025508406 A5 JP2025508406 A5 JP 2025508406A5 JP 2024548386 A JP2024548386 A JP 2024548386A JP 2024548386 A JP2024548386 A JP 2024548386A JP 2025508406 A5 JP2025508406 A5 JP 2025508406A5
Authority
JP
Japan
Prior art keywords
treatment
compound
antidepressant
necessary
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508406A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/013098 external-priority patent/WO2023158668A1/en
Publication of JP2025508406A publication Critical patent/JP2025508406A/ja
Publication of JP2025508406A5 publication Critical patent/JP2025508406A5/ja
Pending legal-status Critical Current

Links

JP2024548386A 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド Pending JP2025508406A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US63/310,581 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US63/337,828 2022-05-03
US202363482200P 2023-01-30 2023-01-30
US63/482,200 2023-01-30
PCT/US2023/013098 WO2023158668A1 (en) 2022-02-16 2023-02-15 Neuroactive steroids for treatment of cns-related disorders

Publications (2)

Publication Number Publication Date
JP2025508406A JP2025508406A (ja) 2025-03-26
JP2025508406A5 true JP2025508406A5 (https=) 2026-02-25

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548386A Pending JP2025508406A (ja) 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド

Country Status (11)

Country Link
US (1) US20250295674A1 (https=)
EP (1) EP4479032A1 (https=)
JP (1) JP2025508406A (https=)
KR (1) KR20240148425A (https=)
CN (1) CN119072304A (https=)
AU (1) AU2023220976A1 (https=)
CA (1) CA3252357A1 (https=)
IL (1) IL315023A (https=)
MX (1) MX2024009974A (https=)
TW (1) TW202341995A (https=)
WO (1) WO2023158668A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
WO2022232504A1 (en) * 2021-04-29 2022-11-03 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2025508406A5 (https=)
JP2009511618A (ja) 中度から重度のむずむず脚症候群(rls)を治療するためのプラミペキソールの使用
JP6406713B2 (ja) 低用量薬剤によるうつ病および他の疾患の処置
JP7265990B2 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
CN101431990B (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
JP2023100904A5 (https=)
JPH08208471A (ja) 薬物反応の増強作用
JP2009538331A (ja) 抑うつ障害のための治療
JP2013544850A5 (https=)
JP2023143940A5 (https=)
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
JP2021511365A5 (https=)
JP2022506113A5 (https=)
JP2006506461A (ja) ミルナシプランのパルス型放出組成物
JP2005511736A (ja) 新規塩酸ベンラファクシンの結晶多形体およびその作成方法
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
WO2008037045A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
JP2021530568A5 (https=)
HUP0104514A2 (en) The use of aril-substituted cyclobutylalkylamines for treating urinary incontinence
CN104271131A (zh) 包含(1r,4r)-6’-氟-N,N-二甲基-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺和抗抑郁药的药物组合物
EA003546B1 (ru) Новые способы лечения нервных расстройств
CN1468094A (zh) 含有依匹期汀及假麻黄碱的新药物组合物
JP2025500344A5 (https=)
CN113194950B (zh) 早泄(pe)的治疗和预防